Annual report
Annual Report 2026
Source: Nse
Vaishali Pharma Limited (VAISHALI)
Small CapIndustrials stocks · Small cap · NSE
Vaishali Pharma Limited operates in Defence / Aerospace, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 05:50 pm ISTDetails
Quote19 Oct, 05:50 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:43 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage12/14 · 86%
Valuation2026-07-20 · Rf 6.8% · Industrials P/E 26.2 (n=537)
Technical timing lens
Trend score and candlestick chart
36BearishSMA20 -2.1% / mo · MACD −
Stock trend: 30
Sector RS: 46
Sector 3M: -7.1% vs Nifty 500 -5.6%
Industrials FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
VAISHALID candles · FIT view-6.1%Latest close ₹7.54 on 2026-10-19
Bar
-8.6%
RSI
32
MACD hist
-0.08
52W pos
44%
2026-10-19O ₹8.25H ₹8.25L ₹7.50C ₹7.54Vol 71,977 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
VAISHALINifty India ManufacturingNifty 500
- VAISHALI
- -3.6%
- Nifty 500
- -5.6%
- Nifty India Manufacturing
- -5.8%
- Vs Nifty 500
- +2.0 pp
Chart stats
19 Oct 2026- From 52W high
- -34.3%
- 52W range position
- 42%
- ATR (14)
- 7.4%
- Volume vs 20D
- 0.45x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹7.5 - ₹9.1
₹11.5
₹4.8 - ₹11.5
₹0.6
Latest completed session
20-session average
32.8% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend argues for patience, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · OVERVALUED24
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Pending data—
Revenue NDF · PAT NDF YoY
Technical
Bearish36
Price trend and sector-relative-strength timing.
Valuation
Legacy model+43.6%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence58
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Pending dataYoY comparison unavailable - result verdict pending data
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹22.9 Cr | NDF | -15.0% |
| EBITDA | ₹1.5 Cr | NDF | +845.0% |
| Operating margin | 6.5% | NDF | +725 bps |
| PAT | ₹1.6 Cr | NDF | +278.1% |
| PAT margin | 6.8% | NDF | +525 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 24.20
- P/B
- 1.56
- EV/EBITDA
- 25.40
- Market Cap
- 108.00Cr
Profitability
- ROE
- 6.02%
- ROCE
- —
- ROA
- 3.25%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 18.00%
- EPS 5Y
- 18.00%
- Revenue 3Y
- -15.00%
- EPS 3Y
- -15.00%
Balance Sheet
- Debt/Equity
- 0.28
- Interest Coverage
- 2.00×
- Altman Z
- 2.88
- Book Value
- 5.30
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- —
- EPS TTM
- 0.34
Shareholding
- Promoter Hold
- 30.54%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 52%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 22.9-15.0% vs prev
Net Profit
₹ CrLatest: 1.6+278.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 32.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~2.2% over last month) — short-term momentum negative.
- RSI(14) at 32 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 32% off 52W high · 59% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
34
RS percentile
Stage 1 Base / Transition
1M return
-14.2%
3M return
-3.6%
6M return
-14.3%
1Y return
-25.8%
RS 1D
-2
RS 20D
-28
Sector rank
#2
Industry rank
#6
Stage evidence
- Price is within 0.1% of the 30-week proxy.
- The 30-week proxy changed +2.6% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 67.64-2.45%
RS vs Nifty 50068
Valuation & peers
U-Score 24 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 24 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation12/30
Growth13/25
Quality0/20
Balance Sheet6/15
Cash Flow0/10
Piotroski
4/9 (+1)
Penalties
-8
Raw sum
24
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
24/100 · legacy band OVERVALUED
Positive drivers
- Fair-value margin of safety is positive at 43.6%.
- Growth contributes 13/25 to the score.
- Valuation contributes 12/30 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
24.2
PB
1.6
EV/EBITDA
25.4
ROE
6.0%
ROCE
—
FCF Yield
—
Debt/Equity
0.3
MoS
+43.6%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
24
Previous: 24
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
+43.6%
Previous: +43.6%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
21
21
21
21
21
24
24
24
24
24
24
24
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹6.37
-18.4% MoS
Growth-justified P/E
39.3
Growth-justified Value
₹13.36
+43.6% MoS
PEG
1.34
Comparable companies
Peers
Business-comparable peers in Industrials — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SHAHALLOYS
Small
Shah Alloys Limited
Defence / Aerospace
match 157
43
23.6
-55.5%
+58%
WATCHLIST
KAUSHALYA
Small
Kaushalya Infrastructure Development Corporation Limited
Defence / Aerospace
match 156
14
—
0.4%
—
OVERVALUED
UNIMECH
Small
Unimech Aerospace and Manufacturing Limited
Defence / Aerospace
match 146
28
130.0
8.0%
-202%
OVERVALUED
SHALPAINTS
Small
Shalimar Paints Limited
Defence / Aerospace
match 145
16
—
-21.4%
—
OVERVALUED
MTARTECH
Micro
Mtar Technologies Limited
Defence / Aerospace
match 139
32
175.0
12.4%
-321%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Vaishali Pharma Limited operates in Defence / Aerospace, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
58Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 22nd percentile of the scored universe and 18th percentile within Industrials. Main check: cash conversion is weak at 43/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
6 docs text-extracted · 2 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
22nd percentile
overall median 67 · Industrials: 18th pctile, median 68 · Small: 25th pctile, median 66
Evidence depth
Financial-only
6 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
70
acceptable · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
52
watch · capital discipline
Results
55
watch · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
Trust risks
- ▸Promoter holding fell 1.1%.
- ▸Only 0 years of positive FCF.
- ▸ROE is low at 6%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Vaishali Pharma Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual report
Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.